Dermatologic adverse events of cancer immunotherapy with anti-PD-1 and anti-PD-L1 monoclonal antibodies
AbstractThe article describes major types of dermatologic immune-related adverse events during treatment with PD-1/PD-L1 immune checkpoint inhibitors. We present several clinical cases, describe current topical and systemic therapies of patients with such type of immune-mediated adverse events. In addition, the stepwise approach to the management ofpatients with dermatologic immune-related adverse events based on clinical course and severity grading is presented.
Keywords:immunotherapy; immune checkpoint inhibitors; PD-1/PD-L1; skin toxicity; immune-related adverse events; supportive care; oncodermatology
For citation: Shatokhina E.A., Polonskaia A.S., Kruglova L.S., Shatokhin M.N. Dermatologic adverse events of antitumor immunotherapy with anti-PD-1 and anti-PD-L1 monoclonal antibodies. Immunologiya. 2021; 42 (6): 641-54. DOI: https://doi.org/10.33029/0206-4952-2021-42-6-641-654 (in Russian)
Funding. The study had no sponsor support.
Conflict of interests. The authors declare no conflict of interests.
References
1. Hamid O., Robert C., Daud A., Hodi F.S., Hwu W.J., Kefford R., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 2013; 369 (2): 134–44. DOI: http://doi.org/10.1056/NEJMoa1305133
2. Ilie M., Hofman P. Atezolizumab in advanced non-small cell lung cancer. J. Thorac. Dis. 2017; 9 (10): 3603–6. DOI: http://doi.org/10.21037/jtd.2017.09.73
3. Lavacchi D., Roviello G., D’Angelo A. Tumor-agnostic treatment for cancer: when how is better than where. Clin. Drug Investig. 2020; 40 (6): 519–27. DOI: http://doi.org/10.1007/s40261-020-00915-5
4. Zhukov N.V. Targeted and disease-agnostic therapy. What is meant by these terms and what to expect? Russian society of clinical oncology Web portal. Oncology News. URL: https://rosoncoweb.ru/news/oncology/2020/07/27/ (in Russian)
5. Protsenko S.A., Antimonik N.Yu., Bershtein L.M., Zhukova N.V., Novik A.V., Nosov D.A., et al. Practical recommendations on the management of immune-related adverse events. Zlokachestvennye opukholi. Prakticheskie rekomendatsii RUSSCO [Malignant Tumours. Practical Recommendations RUSSCO]. 2020; 10 (3s2): 50. DOI: http://doi.org/10.18027/2224-5057-2020-10-3s2-50 (in Russian)
6. Alatrash G., Jakher H., Stafford P.D., Mittendorf E.A. Cancer immunotherapies, their safety and toxicity. Expert Opin. Drug Saf. 2013; 12 (5): 631–45. DOI: http://doi.org/10.1517/14740338.2013.795944
7. Weber J.S., Yang J.C., Atkins M.B., Disis M.L. Toxicities of Immunotherapy for the practitioner. J. Clin. Oncol. 2015; 33 (18): 2092–9. DOI: http://doi.org/10.1200/JCO.2014.60.0379
8. Schirrmacher V. From chemotherapy to biological therapy: a review of novel concepts to reduce the side effects of systemic cancer treatment. Int. J. Oncol. 2019; 54 (2): 407–19. DOI: http://doi.org/10.3892/ijo.2018.4661
9. Prescribing information for Keytruda®. URL: https://www.vidal.ru/drugs/keytruda (in Russian)
10. Prescribing information for Opdivo®. URL: https://www.vidal.ru/drugs/opdivo (in Russian)
11. Prescribing information for Tecentriq®. URL: https://www.vidal.ru/drugs/tecentriq-1 (in Russian)
12. Prescribing information for Bavensio®. URL: https://www.vidal.ru/drugs/bavensio (in Russian)
13. Francisco L.M., Salinas V.H., Brown K.E., Vanguri V.K., Freeman G.J., Kuchroo V.K., et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J. Exp. Med. 2009; 206 (13): 3015–29. DOI: http://doi.org/10.1084/jem.20090847
14. Curry J.L., Tetzlaff M.T., Nagarajan P., Drucker C., Diab A., Hymes S.R., et al. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J. Cutan. Pathol. 2017; 44 (2): 158–76. DOI: http://doi.org/10.1111/cup.12858
15. Belum V.R., Benhuri B., Postow M.A., Hellmann M.D., Lesokhin A.M., Segal N.H., et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur. J. Cancer. 2016; 60: 12–25. DOI: http://doi.org/10.1016/j.ejca.2016.02.010
16. Menzies A.M., Johnson D.B., Ramanujam S., Atkinson V.G., Wong A.N.M., Park J.J., et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann. Oncol. 2017; 28 (2): 368–76. DOI: http://doi.org/10.1093/annonc/mdw443
17. Collins L.K., Chapman M.S., Carter J.B., Samie F.H. Cutaneous adverse effects of the immune checkpoint inhibitors. Curr. Probl. Cancer. 2017; 41 (2): 125–8. DOI: http://doi.org/10.1016/j.currproblcancer.2016.12.001
18. Naidoo J., Page D.B., Li B.T., Connell L.C., Schindler K., Lacouture M.E., et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann. Oncol. 2015; 26 (12): 2375–91. DOI: http://doi.org/10.1093/annonc/mdv383
19. Ellis S.R., Vierra A.T., Millsop J.W., Lacouture M.E., Kiuru M. Dermatologic toxicities to immune checkpoint inhibitor therapy: a review of histopathologic features. J. Am. Acad. Dermatol. 2020; 83 (4): 1130–43. DO: http://doi.org/10.1016/j.jaad.2020.04.105
20. Dai J., Belum V.R., Wu S., Sibaud V., Lacouture M.E. Pigmentary changes in patients treated with targeted anticancer agents: a systematic review and meta-analysis. J. Am. Acad. Dermatol. 2017; 77 (5): 902–10.e2. DOI: http://doi.org/10.1016/j.jaad.2017.06.044
21. Hua C., Boussemart L., Mateus C., Routier E., Boutros C., Cazenave H., et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol. 2016; 152 (1): 45–51. DOI: http://doi.org/10.1001/jamadermatol.2015.2707
22. Hwang S.J., Carlos G., Wakade D., Byth K., Kong B.Y., Chou S., et al. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. J. Am. Acad. Dermatol. 2016; 74 (3): 455–61.e1. DOI: http://doi.org/10.1016/j.jaad.2015.10.029
23. Nakamura Y., Tanaka R., Asami Y., Teramoto Y., Imamura T., Sato S., et al. Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: a multi-institutional retrospective study. J. Dermatol. 2017; 44 (2): 117–22. DOI: http://doi.org/10.1111/1346-8138.13520
24. Larsabal M., Marti A., Jacquemin C., Rambert J., Thiolat D., Dousset L., et al. Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo. J. Am. Acad. Dermatol. 2017; 76 (5): 863–70. DOI: http://doi.org/10.1016/j.jaad.2016.10.044
25. Hofmann L., Forschner A., Loquai C., Goldinger S.M., Zimmer L., Ugurel S., et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur. J. Cancer. 2016; 60: 190–209. DOI: http://doi.org/10.1016/j.ejca.2016.02.025
26. Shi V.J., Rodic N., Gettinger S., Leventhal J.S., Neckman J.P., Girardi M., et al. Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy. JAMA Dermatol. 2016; 152 (10): 1128–36. DOI: http://doi.org/10.1001/jamadermatol.2016.2226
27. Tetzlaff M.T., Nagarajan P., Chon S., Huen A., Diab A., Omar P., et al. Lichenoid dermatologic toxicity from immune checkpoint blockade therapy: a detailed examination of the clinicopathologic features. Am. J. Dermatopathol. 2017; 39 (2): 121–9. DOI: http://doi.org/10.1097/DAD.0000000000000688
28. Joseph R.W., Cappel M., Goedjen B., Gordon M., Kirsch B., Gilstrap C., et al. Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy. Cancer Immunol. Res. 2015; 3 (1): 18–22. DOI: http://doi.org/10.1158/2326-6066.CIR-14-0134
29. Bonigen J., Raynaud-Donzel C., Hureaux J., Kramkimel N., Blom A., Jeudy G., et al. Anti-PD1-induced psoriasis: a study of 21 patients. J. Eur. Acad. Dermatol. Venereol. 2017; 31 (5): e254–7. DOI: http://doi.org/10.1111/jdv.14011
30. Ruiz-Bañobre J., Abdulkader I., Anido U., León L., López-López R., García-González J. Development of de novo psoriasis during nivolumab therapy for metastatic renal cell carcinoma: immunohistochemical analyses and clinical outcome. APMIS. 2017; 125 (3): 259–63. DOI: http://doi.org/10.1111/apm.12658
31. Dulos J., Carven G.J., van Boxtel S.J., Evers S., Driessen-Engels L.J., Hobo W., et al. PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J. Immunother. 2012; 35 (2): 169–78. DOI: http://doi.org/10.1097/CJI.0b013e318247a4e7
32. Parakh S., Nguyen R., Opie J.M., Andrews M.C. Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma. Australas J. Dermatol. 2017; 58 (3): e109–12. DOI: http://doi.org/10.1111/ajd.12488
33. Chen W.S., Tetzlaff M.T., Diwan H., Jahan-Tigh R., Diab A., Nelson K., et al. Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: a spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions. J. Cutan. Pathol. 2018; 45 (10): 764–73. DOI: http://doi.org/10.1111/cup.13312
34. Naidoo J., Schindler K., Querfeld C., Busam K., Cunningham J., Page D.B., et al. Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1. Cancer Immunol. Res. 2016; 4 (5): 383–9. DOI: http://doi.org/10.1158/2326-6066.CIR-15-0123
35. Damsky W., Kole L., Tomayko M.M. Development of bullous pemphigoid during nivolumab therapy. JAAD Case Rep. 2016; 2 (6): 442–4. DOI: http://doi.org/10.1016/j.jdcr.2016.05.009
36. Coleman E.L., Olamiju B., Leventhal J.S. The life-threatening eruptions of immune checkpoint inhibitor therapy. Clin. Dermatol. 2020; 38 (1): 94–104. DOI: http://doi.org/10.1016/j.clindermatol.2019.10.015
37. Griffin L.L., Cove-Smith L., Alachkar H., Radford J.A., Brooke R., Linton K.M. Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma. JAAD Case Rep. 2018; 4 (3): 229–31. DOI: http://doi.org/10.1016/j.jdcr.2017.09.028
38. Nayar N., Briscoe K., Fernandez Penas P. Toxic epidermal necrolysis-like reaction with severe satellite cell necrosis associated with nivolumab in a patient with ipilimumab refractory metastatic melanoma. J. Immunother. 2016; 39 (3): 149–52. DOI: http://doi.org/10.1097/CJI.0000000000000112
39. Hwang A., Iskandar A., Dasanu C.A. Stevens-Johnson syndrome manifesting late in the course of pembrolizumab therapy. J. Oncol. Pharm. Pract. 2019; 25 (6): 1520–2. DOI: http://doi.org/10.1177/1078155218791314
40. Saw S., Lee H.Y., Ng Q.S. Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patients. Eur. J. Cancer. 2017; 81: 237–9. DOI: http://doi.org/10.1016/j.ejca.2017.03.026
41. Haratake N., Tagawa T., Hirai F., Toyokawa G., Miyazaki R., Maehara Y. Stevens-Johnson syndrome induced by pembrolizumab in a lung cancer patient. J. Thorac. Oncol. 2018; 13 (11): 1798–9. DOI: http://doi.org/10.1016/j.jtho.2018.05.031
42. Vivar K.L., Deschaine M., Messina J., Divine J.M., Rabionet A., Patel N., et al. Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy. J. Cutan. Pathol. 2017; 44 (4): 381–4. DOI: http://doi.org/10.1111/cup.12876
43. Marano A.L., Clarke J.M., Morse M.A., Shah A., Barrow W., Selim M.A., et al. Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy. Br. J. Dermatol. 2019; 181 (3): 580–3. DOI: http://doi.org/10.1111/bjd.17245
44. Shao K., McGettigan S., Elenitsas R., Chu E.Y. Lupus-like cutaneous reaction following pembrolizumab: an immune-related adverse event associated with anti-PD-1 therapy. J. Cutan. Pathol. 2018; 45 (1): 74–7. DOI: http://doi.org/10.1111/cup.13059
45. Birnbaum M.R., Ma M.W., Fleisig S., Packer S., Amin B.D., Jacobson M., et al. Nivolumab-related cutaneous sarcoidosis in a patient with lung adenocarcinoma. JAAD Case Rep. 2017; 3 (3): 208–11. DOI: http://doi.org/10.1016/j.jdcr.2017.02.015
46. Zarbo A., Belum V.R., Sibaud V., Oudard S., Postow M.A., Hsieh J.J., et al. Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors. Br. J. Dermatol. 2017; 176 (6): 1649–52. DOI: http://doi.org/10.1111/bjd.15237
47. Dasanu C.A., Lippman S.M., Plaxe S.C. Persistently curly hair phenotype with the use of nivolumab for squamous cell lung cancer. J. Oncol. Pharm. Pract. 2017; 23 (8): 638–40. DOI: http://doi.org/10.1177/1078155216674355
48. Rivera N., Boada A., Bielsa M.I., Fernández-Figueras M.T., Carcereny E., Moran M.T., et al. Hair repigmentation during immunotherapy treatment with an anti-programmed cell death 1 and anti-programmed cell death ligand 1 agent for lung cancer. JAMA Dermatol. 2017; 153 (11): 1162–5. DOI: http://doi.org/10.1001/jamadermatol.2017.2106
49. Wang D., Zhang S., Ding P., Zhao Y., Zhang X., Zhao Q. Immune-related adverse events mimicking Behcet’s disease in a gastric cancer patient following camrelizumab treatment. Iran. J. Immunol. 2020; 17 (2): 167–71. DOI: http://doi.org/10.22034/iji.2020.85507.1717
50. Le Burel S., Champiat S., Routier E., Aspeslagh S., Albiges L., Szwebel T.A., et al. Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy. Ann. Rheum. Dis. 2018; 77 (3): 468–70. DOI: http://doi.org/10.1136/annrheumdis-2016-210820
51. Coleman E., Ko C., Dai F., Tomayko M.M., Kluger H., Leventhal J.S. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. J. Am. Acad. Dermatol. 2019; 80 (4): 990–7. DOI: http://doi.org/10.1016/j.jaad.2018.10.062
52. Davick J.J., Wick M.R., Gru A.A. Development of a biclonal cutaneous T-cell lymphoproliferative process during treatment with immune checkpoint inhibitors for metastatic melanoma. Melanoma Res. 2017; 27 (4): 383–6. DOI: http://doi.org/10.1097/CMR.0000000000000371
53. Freites-Martinez A., Kwong B.Y., Rieger K.E., Coit D.G., Colevas A.D., Lacouture M.E. Eruptive keratoacanthomas associated with pembrolizumab therapy. JAMA Dermatol. 2017; 153 (7): 694–7. DOI: http://doi.org/10.1001/jamadermatol.2017.0989
54. Tetzlaff M.T., Jazaeri A.A., Torres-Cabala C.A., Korivi B.R., Landon G.A., Nagarajan P., et al. Erythema nodosum-like panniculitis mimicking disease recurrence: a novel toxicity from immune checkpoint blockade therapy – report of 2 patients. J. Cutan. Pathol. 2017; 44 (12): 1080–6. DOI: http://doi.org/10.1111/cup.13044
55. US Department of Health and Human Services, et al. Common Terminology Criteria for Adverse Events (CTCAE) Version 5. Published: November 27. URL: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf
56. Choi J., Anderson R., Blidner A., Cooksley T., Dougan M., Glezerman I., et al. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors. Support. Care Cancer. 2020; 28 (12): 6119–28. DOI: http://doi.org/10.1007/s00520-020-05706-4
57. Sibaud V. Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am. J. Clin. Dermatol. 2018; 19 (3): 345–61. DOI: http://doi.org/10.1007/s40257-017-0336-3
58. Phillips G.S., Wu J., Hellmann M.D., Postow M.A., Rizvi N.A., Freites-Martinez A., et al. Treatment outcomes of immune-related cutaneous adverse events. J. Clin. Oncol. 2019; 37 (30): 2746–58. DOI: http://doi.org/10.1200/JCO.18.02141
59. Santini D., Vincenzi B., Guida F.M., Imperatori M., Schiavon G., Venditti O., et al. Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study. Lancet Oncol. 2012; 13 (10): 1020–4. DOI: http://doi.org/10.1016/S1470-2045(12)70373-X
60. Rapoport B.L., van Eeden R., Sibaud V., Epstein J.B., Klastersky J., Aapro M., et al. Supportive care for patients undergoing immunotherapy. Support. Care Cancer. 2017; 25 (10): 3017–30. DOI: http://doi.org/10.1007/s00520-017-3802-9
61. Brahmer J.R., Lacchetti C., Thompson J.A. Management of Immune-Related Adverse Events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary. J. Oncol. Pract. 2018; 14 (4): 247–9. DOI: http://doi.org/10.1200/JOP.18.00005
62. Muntyanu A., Netchiporouk E., Gerstein W., Gniadecki R., Litvinov I.V. Cutaneous immune-related adverse events (irAEs) to immune checkpoint inhibitors: a dermatology perspective on management. J. Cutan. Med. Surg. 2021; 25 (1): 59–76. DOI: http://doi.org/10.1177/1203475420943260
63. Gudima G.O., Khaitov R.M., Kudlay D.A., Khaitov M.R. Molecular immunological aspects of diagnostics, prevention and treatment of coronavirus infection. Immunologiya. 2021; 42 (3): 198–210. DOI: https://doi.org/10.33029/0206-4952-2021-42-3-198-210 (in Russian)